{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["112(2)"],"submitter":["Choi YJ"],"pubmed_abstract":["<h4>Background</h4>Pemetrexed has shown a favourable response rate of about 30% with minimal toxicity when used as a single agent for treatment of advanced urothelial carcinoma. This phase II study evaluated the efficacy and safety of pemetrexed plus cisplatin in advanced urothelial carcinoma.<h4>Methods</h4>This multicentre, single-arm, open-label, phase II clinical trial enrolled patients who had advanced urothelial carcinoma, ECOG PS 0-2, and measurable disease. Pemetrexed 500 mg m(-2) with cisplatin 70 mg m(-2) on day 1 were administered every 3 weeks. The primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity.<h4>Results</h4>A total of 42 patients were enrolled (median age, 66 years; ECOG 0-"],"journal":["British journal of cancer"],"pagination":["260-5"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4453451"],"repository":["biostudies-literature"],"pubmed_title":["Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17)."],"pmcid":["PMC4453451"],"pubmed_authors":["Ahn JH","Hong JH","Choi YJ","Lee SH","You D","Lee JL","Ahn H","Hong B","Lee KH"],"additional_accession":[]},"is_claimable":false,"name":"Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).","description":"<h4>Background</h4>Pemetrexed has shown a favourable response rate of about 30% with minimal toxicity when used as a single agent for treatment of advanced urothelial carcinoma. This phase II study evaluated the efficacy and safety of pemetrexed plus cisplatin in advanced urothelial carcinoma.<h4>Methods</h4>This multicentre, single-arm, open-label, phase II clinical trial enrolled patients who had advanced urothelial carcinoma, ECOG PS 0-2, and measurable disease. Pemetrexed 500 mg m(-2) with cisplatin 70 mg m(-2) on day 1 were administered every 3 weeks. The primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity.<h4>Results</h4>A total of 42 patients were enrolled (median age, 66 years; ECOG 0-","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jan","modification":"2025-04-04T18:50:52.653Z","creation":"2019-03-27T01:52:38Z"},"accession":"S-EPMC4453451","cross_references":{"pubmed":["25429526"],"doi":["10.1038/bjc.2014.591"]}}